not tagged
Treg therapeutics
['lung', 'gbm', 'rcc,(-irccs),(-srcc),(-urcc)']
#esmo22 anti-cd25 is a novel treg therapeutic target relevant to lung cancer, rcc and gbm, evaluated in vitro&amp; in vivo by &amp; his team and now brought to the clinic in a phase i trial 
Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity at Beaumont RCSI Cancer Centre Dublin; Adjunct Professor Johns Hopkins University